BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38194688)

  • 1. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
    Crespiatico I; Zaghi M; Mastini C; D'Aliberti D; Mauri M; Mercado CM; Fontana D; Spinelli S; Crippa V; Inzoli E; Manghisi B; Civettini I; Ramazzotti D; Sangiorgio V; Gengotti M; Brambilla V; Aroldi A; Banfi F; Barone C; Orsenigo R; Riera L; Riminucci M; Corsi A; Breccia M; Morotti A; Cilloni D; Roccaro A; Sacco A; Stagno F; Serafini M; Mottadelli F; Cazzaniga G; Pagni F; Chiarle R; Azzoni E; Sessa A; Gambacorti-Passerini C; Elli EM; Mologni L; Piazza R
    Blood; 2024 Apr; 143(14):1399-1413. PubMed ID: 38194688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic SETBP1 mutations in myeloid neoplasms.
    Makishima H
    Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
    Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
    Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
    Carratt SA; Kong GL; Curtiss BM; Schonrock Z; Maloney L; Maniaci BN; Blaylock HZ; Baris A; Druker BJ; Braun TP; Maxson JE
    Blood; 2022 Aug; 140(6):644-658. PubMed ID: 35482940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic SETBP1 mutations in myeloid malignancies.
    Makishima H; Yoshida K; Nguyen N; Przychodzen B; Sanada M; Okuno Y; Ng KP; Gudmundsson KO; Vishwakarma BA; Jerez A; Gomez-Segui I; Takahashi M; Shiraishi Y; Nagata Y; Guinta K; Mori H; Sekeres MA; Chiba K; Tanaka H; Muramatsu H; Sakaguchi H; Paquette RL; McDevitt MA; Kojima S; Saunthararajah Y; Miyano S; Shih LY; Du Y; Ogawa S; Maciejewski JP
    Nat Genet; 2013 Aug; 45(8):942-6. PubMed ID: 23832012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.
    Alvarez-Larrán A; López-Guerra M; Rozman M; Correa JG; Hernández-Boluda JC; Tormo M; Martínez D; Martín I; Colomer D; Esteve J; Cervantes F
    Ann Hematol; 2019 Oct; 98(10):2319-2328. PubMed ID: 31396671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
    Al-Ghamdi YA; Lake J; Bagg A; Thakral B; Wang SA; Bueso-Ramos C; Masarova L; Verstovsek S; Rogers HJ; Hsi ED; Gralewski JH; Chabot-Richards D; George TI; Rets A; Hasserjian RP; Weinberg OK; Parilla M; Arber DA; Padilla O; Orazi A; Tam W
    Mod Pathol; 2023 Mar; 36(3):100016. PubMed ID: 36788093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
    Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
    Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
    Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
    [No Abstract]   [Full Text] [Related]  

  • 10. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
    Fontana D; Ramazzotti D; Aroldi A; Redaelli S; Magistroni V; Pirola A; Niro A; Massimino L; Mastini C; Brambilla V; Bombelli S; Bungaro S; Morotti A; Rea D; Stagno F; Martino B; Campiotti L; Caocci G; Usala E; Merli M; Onida F; Bregni M; Elli EM; Fumagalli M; Ciceri F; Perego RA; Pagni F; Mologni L; Piazza R; Gambacorti-Passerini C
    Hemasphere; 2020 Dec; 4(6):e497. PubMed ID: 33196013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Yao XY; Zhou JD; Yang J; Zhang W; Ma JC; Wen XM; Yao DM; Xu ZJ; Wu DH; He PF; Qian J; Lin J
    Pathol Res Pract; 2018 May; 214(5):706-712. PubMed ID: 29549983
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Linder K; Iragavarapu C; Liu D
    Biomark Res; 2017; 5():33. PubMed ID: 29225884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.
    Nguyen N; Vishwakarma BA; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
    Oncotarget; 2016 Dec; 7(52):86300-86312. PubMed ID: 27863435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
    Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
    BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
    Gurney M; Chekkaf I; Baranwal A; Basmaci R; Katamesh B; Greipp P; Foran JM; Badar T; Mangaonkar AA; Begna KH; Gangat N; Patnaik MM; Litzow MR; Shah MV; Viswanatha DS; He R; Alkhateeb HB; Al-Kali A
    Br J Haematol; 2023 Jul; 202(2):279-283. PubMed ID: 37144345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.
    Martinaud C; Desterke C; Konopacki J; Vannucchi AM; Pieri L; Guglielmelli P; Dupriez B; Ianotto JC; Boutin L; Lataillade JJ; Le Bousse-Kerdilès MC
    Genom Data; 2015 Sep; 5():1-2. PubMed ID: 26484208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic genetic alterations predict hematological progression in GATA2 deficiency.
    Largeaud L; Collin M; Monselet N; Vergez F; Fregona V; Larcher L; Hirsch P; Duployez N; Bidet A; Luquet I; Bustamante J; Dufrechou S; Prade N; Nolla M; Hamelle C; Tavitian S; Habib C; Meynier M; Bellanne-Chantelot C; Donadieu J; De Fontbrune FS; Fieschi C; Ferster A; Delhommeau F; Delabesse E; Pasquet M
    Haematologica; 2023 Jun; 108(6):1515-1529. PubMed ID: 36727400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare evolution of
    Hirao M; Watanabe K; Tsukada Y; Kunieda H; Osada M; Yamazaki K; Denda R; Okamoto S; Kikuchi T
    Leuk Res Rep; 2022; 17():100311. PubMed ID: 35497674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.